Combination therapy of zonisamide and Bupropion for weight reduction in obese women: A preliminary, randomized, open-label study

被引:56
作者
Gadde, Kishore M. [1 ]
Yonish, Gretchen M. [1 ]
Foust, Mariko S. [1 ]
Wagner, H. Ryan [1 ]
机构
[1] Duke Univ, Med Ctr, Obest Clin Trails Program, Durham, NC 27710 USA
关键词
D O I
10.4088/JCP.v68n0809
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: Zonisamide and bupropion have been investigated for weight reduction in obese adults. We conducted a preliminary study comparing the effect on body weight of the combination of these 2 drugs versus zonisamide monotherapy. Method: This was a 12-week, randomized, openlabel. parallel-group comparison of 2 active interventions conducted from October 2003 to June 2004. Eighteen obese women (mean [SE] body mass index of 36.8 [1.2] kg/m(2)) were randomly assigned to receive the combination of zonisamide and bupropion (N = 9) or zonisamide alone (N = 9). All subjects were prescribed a balanced hypocaloric diet (500 kcal/day deficit) and compliance was monitored with self-rated food diaries. Zonisamide therapy was started at 100 mg/day, with a gradual increase to 400 mg/day over 4 weeks for both groups. In addition. the group assigned to combination therapy received bupropion. which was started at 100 mg/day, with an increase to 200 mg/day after 2 weeks. Zonisamide was administered at night and bupropion in the morning. Body weight in kilograms was the primary outcome measure. Results: In an intent-to-treat analysis, carrying the last observation forward for all randomly assigned participants with at least 1 postbaseline assessment, the combination group lost more body weight than the zonisamide group (mean [SE] 7.2 [1.2] kg [7.5%] vs. 2.9 [0.7] kg [3.1%]; F = 4.7, df = 4,56; p = .003) during the 12-week period. For the subset of 12 patients (combination, N = 7; zonisamide, N = 5) that completed the full 12-week treatment, the mean (SE) weight loss was 8.1 (1.4) kg (8.5%) for the combination group versus 3.0 (0.9) kg (3.3%) for the zonisamide group (F = 4.6, df = 4,40; p = .004). Six subjects in the combination group and 2 in the zonisamide group lost at least 5% of body weight. Conclusion: In this short-term, open-label, preliminary trial, combination treatment of zonisamide and bupropion resulted in more weight loss than treatment with zonisamide alone.
引用
收藏
页码:1226 / 1229
页数:4
相关论文
共 6 条
[1]   Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial [J].
Anderson, JW ;
Greenway, FL ;
Fujioka, K ;
Gadde, KM ;
McKenney, J ;
O'Neil, PM .
OBESITY RESEARCH, 2002, 10 (07) :633-641
[2]  
Gadbury G L, 2003, Obes Rev, V4, P175, DOI 10.1046/j.1467-789X.2003.00109.x
[3]   Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women [J].
Gadde, KM ;
Parker, CB ;
Maner, LG ;
Wagner, HR ;
Logue, EJ ;
Drezner, MK ;
Krishnan, KRR .
OBESITY RESEARCH, 2001, 9 (09) :544-551
[4]   Zonisamide for weight loss in obese adults - A randomized controlled trial [J].
Gadde, KM ;
Franciscy, DM ;
Wagner, HR ;
Krishnan, KRR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14) :1820-1825
[5]   Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms [J].
Jain, AK ;
Kaplan, RA ;
Gadde, KM ;
Wadden, TA ;
Allison, DB ;
Brewer, ER ;
Leadbetter, RA ;
Richard, N ;
Haight, B ;
Jamerson, BD ;
Buaron, KS ;
Metz, A .
OBESITY RESEARCH, 2002, 10 (10) :1049-1056
[6]  
World Health Organization, 1985, WHO EN PROT REQ